Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
How can i apply for yervoy discountsCan lipitor dosage be reduced after weight lossDo you offer expedited shipping for advilWhat quality checks does aurobindo use for clonazepam productionHow does vascepa compare to other long term treatments
A generic version of ruxolitinib was filed in the USA in December 2015. This filing aligns with the patent expiration of the drug, as reported by Drug Patent Watch [1] and Fierce Pharma [2]. Ruxolitinib is an important drug used in the treatment of oncology, cancer, and hematologic malignancies, as noted by the FDA [3]. The availability of a generic version of ruxolitinib can potentially increase accessibility and affordability of this critical medication for patients in need. Sources: [1] https://www.drugpatentwatch.com/p/tradename/RUXOLITINIB [2] https://www.fiercepharma.com/special-report/top-15-blockbuster-patent-expirations-coming-decade [3] https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications
Follow-up: When was the generic version of ruxolitinib approved? What are the benefits of using generic ruxolitinib? Has the availability of generic ruxolitinib impacted pricing?
DrugPatentWatch - Make Better Decisions © thinkBiotech LLC 2004 - 2024. All rights reserved.